Total Payments
$1,877
2023 Payments
$97.69
Companies
8
Transactions
46
Medicare Patients
10,291
Medicare Billing
$2.0M
Payment Breakdown by Category
Food & Beverage$1,369 (73.0%)
Education$507.67 (27.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,369 | 37 | 73.0% |
| Education | $507.67 | 9 | 27.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $669.53 | 13 | $0 (2023) |
| Melinta Therapeutics, Inc. | $589.65 | 17 | $0 (2019) |
| Allergan Inc. | $336.70 | 5 | $0 (2018) |
| The Medicines Company | $111.31 | 1 | $0 (2017) |
| Gilead Sciences, Inc. | $91.01 | 5 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $31.91 | 2 | $0 (2017) |
| Janssen Biotech, Inc. | $29.11 | 2 | $0 (2019) |
| ABBVIE INC. | $17.70 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $97.69 | 2 | Astellas Pharma US Inc ($79.99) |
| 2022 | $119.94 | 2 | Astellas Pharma US Inc ($119.94) |
| 2021 | $69.94 | 2 | Astellas Pharma US Inc ($69.94) |
| 2020 | $39.95 | 1 | Astellas Pharma US Inc ($39.95) |
| 2019 | $307.62 | 10 | Astellas Pharma US Inc ($139.95) |
| 2018 | $864.78 | 22 | Melinta Therapeutics, Inc. ($512.05) |
| 2017 | $377.00 | 7 | Astellas Pharma US Inc ($123.16) |
All Payment Transactions
46 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/19/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 07/28/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/08/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 08/08/2022 | Astellas Pharma US Inc | — | Education | In-kind items and services | $39.95 | General |
| 08/16/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $39.95 | General |
| 08/16/2021 | Astellas Pharma US Inc | — | Education | In-kind items and services | $29.99 | General |
| 08/24/2020 | Astellas Pharma US Inc | — | Education | In-kind items and services | $39.95 | General |
| 09/09/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $39.95 | General |
| 04/05/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.58 | General |
| 03/26/2019 | Astellas Pharma US Inc | CRESEMBA (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 03/18/2019 | Melinta Therapeutics, Inc. | Vabomere (Drug) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: ANTIBIOTICS | ||||||
| 02/11/2019 | Melinta Therapeutics, Inc. | Vabomere (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: ANTIBIOTICS | ||||||
| 02/06/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.81 | General |
| 02/06/2019 | Janssen Biotech, Inc. | Symtuza (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 02/05/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.02 | General |
| 01/11/2019 | Melinta Therapeutics, Inc. | Vabomere (Drug) | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: ANTIBIOTICS | ||||||
| 01/04/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.56 | General |
| 11/02/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.04 | General |
| 10/30/2018 | Astellas Pharma US Inc | CRESEMBA (Drug) | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/12/2018 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/29/2018 | Janssen Biotech, Inc. | Symtuza (Drug) | Food and Beverage | In-kind items and services | $13.01 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 09/10/2018 | Melinta Therapeutics, Inc. | Baxdela (Drug), Vabomere, Orbactiv | Food and Beverage | Cash or cash equivalent | $120.31 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 08/20/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $158.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/25/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $57.95 | General |
| 07/06/2018 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $51.96 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 2,475 | 158,997 | $1.7M | $431,350 |
| 2022 | 27 | 2,858 | 330,461 | $2.3M | $574,297 |
| 2021 | 21 | 2,630 | 306,550 | $2.0M | $540,812 |
| 2020 | 21 | 2,328 | 217,512 | $1.6M | $447,228 |
Total Patients
10,291
Total Services
1,013,520
Medicare Billing
$2.0M
Procedure Codes
103
All Medicare Procedures & Services
103 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 729 | 1,123 | $331,285 | $107,631 | 32.5% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2023 | 23 | 7,500 | $232,500 | $88,690 | 38.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 479 | 748 | $198,220 | $47,760 | 24.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 152 | 887 | $199,575 | $43,576 | 21.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 152 | 247 | $134,432 | $33,351 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 197 | 281 | $107,879 | $27,718 | 25.7% |
| 96521 | Refilling and maintenance of portable pump | Office | 2023 | 44 | 134 | $50,250 | $13,042 | 26.0% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 47 | 47 | $21,150 | $10,281 | 48.6% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 56 | 56 | $21,000 | $8,796 | 41.9% |
| 99310 | Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 56 | 64 | $16,000 | $7,844 | 49.0% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 43 | 686 | $56,245 | $7,373 | 13.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 42 | 42 | $28,155 | $6,722 | 23.9% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 45 | 143,500 | $165,435 | $5,931 | 3.6% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 44 | 52 | $8,840 | $4,442 | 50.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 19 | 149 | $14,020 | $3,329 | 23.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 50 | 60 | $16,362 | $3,190 | 19.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $8,611 | $2,008 | 23.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $5,250 | $1,959 | 37.3% |
| J0743 | Injection, cilastatin sodium; imipenem, per 250 mg | Office | 2023 | 11 | 240 | $17,520 | $1,406 | 8.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 12 | 12 | $6,078 | $1,293 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 14 | 15 | $5,759 | $1,176 | 20.4% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 23 | 25 | $2,125 | $1,028 | 48.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 11 | $3,000 | $789.36 | 26.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 34 | 1,776 | $63,120 | $725.36 | 1.1% |
| J0692 | Injection, cefepime hydrochloride, 500 mg | Office | 2023 | 32 | 568 | $25,110 | $559.27 | 2.2% |
About Dr. Natan Kraitman, M.D
Dr. Natan Kraitman, M.D is a Infectious Disease healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/24/2013. The National Provider Identifier (NPI) number assigned to this provider is 1568806222.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Natan Kraitman, M.D has received a total of $1,877 in payments from pharmaceutical and medical device companies, with $97.69 received in 2023. These payments were reported across 46 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($1,369).
As a Medicare-enrolled provider, Kraitman has provided services to 10,291 Medicare beneficiaries, totaling 1,013,520 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 103 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Sarasota, FL
- Active Since 04/24/2013
- Last Updated 04/20/2021
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1568806222
Products in Payments
- Baxdela (Drug) $512.05
- AVYCAZ (Drug) $257.31
- CRESEMBA (Drug) $138.65
- VABOMERE (Drug) $111.31
- Vabomere (Drug) $77.60
- DALVANCE (Drug) $69.66
- DIFICID (Drug) $31.91
- Symtuza (Drug) $29.11
- TEFLARO (Drug) $27.43
- Cresemba (Drug) $23.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Sarasota
Dr. Lavinia Suciu, M.d, M.D
Infectious Disease — Payments: $6,987
Infectious Disease $6,987
Andrew Krinsky, Md, MD
Infectious Disease — Payments: $6,044
Infectious Disease $6,044
Manuel Gordillo, Md, MD
Infectious Disease — Payments: $3,558
Infectious Disease $3,558
Rishi Bhattacharyya, Md, MD
Infectious Disease — Payments: $2,529
Infectious Disease $2,529
Sudha Tallapragada, Md, MD
Infectious Disease — Payments: $1,461
Infectious Disease $1,461
Pablo Dubon, Md, MD
Infectious Disease — Payments: $807.66
Infectious Disease $807.66